Format

Send to

Choose Destination
Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print]

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

Author information

1
Rheumatology, Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, The Netherlands m.lami@reade.nl.
2
Rheumatology, Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, The Netherlands.
3
Amsterdam Rheumatology and Immunology Center | Amsterdam Medical Center, VU Medical Center, Amsterdam, The Netherlands.
4
Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
5
Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.

KEYWORDS:

DMARDs (biologic); anti-TNF; pharmacokinetics; rheumatoid arthritis

Conflict of interest statement

Competing interests: MJA has no conflicts of interest to report. CLK has received honoraria for lectures from Pfizer. MTN has received research funding or speaking/consultancy honoraria from AbbVie, Pfizer, Merck, Roche, BMS, UCB, Eli Lilly, Celgene and Janssen. RFvV has received research support and grants from AbbVie, Amgen, BMS, GSK, Pfizer, Roche and UCB, and honoraria for consultancy from AbbVie, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB and Vertex. TR has received honoraria for lectures from Pfizer, AbbVie and Regeneron, and a research grant from Genmab. MB has received consultancy from Pfizer, BMS, UCB and Teva. GJW has received research funding from Pfizer and honoraria for lectures and in advisory boards of Pfizer, UCB, BMS, AbbVie, Novartis and Biogen.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center